Tatva Chintan Pharma Chem Limited has informed stock exchanges about significant changes to its natural gas supply arrangements following the implementation of the Natural Gas Supply Regulation Order 2026. The pharmaceutical and specialty chemicals manufacturer received communication from Gujarat Gas Limited on 13 March 2026 regarding the new regulatory framework that will impact its manufacturing operations while actively seeking alternative fuel options.

Regulatory Changes and Supply Restrictions

The Natural Gas Supply Regulation Order 2026, issued by the Ministry of Petroleum and Natural Gas on 09 March 2026 under the Essential Commodities Act 1955, introduces substantial changes to gas allocation and pricing mechanisms. The order was implemented as a response to geopolitical conflicts in the Middle East that have disrupted natural gas availability.

Under the new framework, gas supply to industrial consumers, including Tatva Chintan's manufacturing facilities, will be maintained at 80% of the past six months' average gas consumption, subject to operational availability. The supply and allocation will be governed by a pooled price mechanism as notified by the Petroleum Planning & Analysis Cell (PPAC), which will determine the final retail sale price for the company's units.

Impact on Operations and Mitigation Measures

The government mandate supersedes existing provisions of the company's Gas Sales Agreement regarding both pricing and contract quantities. This regulatory change affects the fundamental terms under which Tatva Chintan has been operating its gas-dependent manufacturing processes.

To address these challenges, the company has implemented several mitigation strategies:

• Arranged alternative fuel sources as permitted by Gujarat Pollution Control Board (GPCB)
• Optimized production processes to minimize impact on output
• Established monitoring systems to track developments

Financial Implications and Outlook

While Tatva Chintan has acknowledged that the potential financial impact of the gas shortage and revised pricing mechanism cannot be fully quantified at this stage, the company is actively monitoring the situation. The pooled pricing mechanism introduced by PPAC may result in different cost structures compared to the previous gas sales agreement terms.

The company has committed to keeping stock exchanges informed of any material updates as the situation develops. This proactive disclosure approach demonstrates the company's commitment to maintaining transparency with stakeholders regarding operational challenges that may affect business performance.

Regulatory Compliance and Communication

Tatva Chintan's disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015. The company secretary and compliance officer, Ishwar Nayi, signed the communication on 14 March 2026, ensuring timely compliance with regulatory requirements. The information has been made available on the company's website at www.tatvachintan.com for stakeholder access.

Tatva chintan pharma Chem Limited has announced a scheduled virtual investor meeting with Emerge Capital, demonstrating the company's commitment to maintaining transparent investor relations and regulatory compliance.

Meeting Details and Schedule

The company has formally disclosed its upcoming investor engagement through a regulatory filing dated March 14, 2026. The meeting details are structured as follows:

Regulatory Compliance Framework

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This regulation mandates listed companies to inform stock exchanges about material events and information that could impact investor decisions.

The company has specifically clarified that discussions during the interaction will be limited to publicly available information only. No confidential or unpublished price sensitive information (UPSI) will be shared during the meeting, ensuring compliance with insider trading regulations.

Information Accessibility

Tatva Chintan Pharma Chem Limited has committed to making the meeting information available on its official website at www.tatvachintan.com . This approach ensures broader accessibility of information to all stakeholders and maintains transparency standards.

The company has noted that the scheduled meeting is subject to change, providing flexibility while maintaining proper disclosure protocols. The filing was signed by Ishwar Nayi, Company Secretary and Compliance Officer, on March 14, 2026, reflecting the company's adherence to corporate governance practices.